Cravit/Cravit IV

Cravit/Cravit IV



Daiichi Sankyo


Concise Prescribing Info
Levofloxacin hemihydrate
Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosocomial pneumonia, complicated & uncomplicated (mild to moderate) skin & skin structure infections (SSSI), UTI, acute pyelonephritis, chronic bacterial prostatitis.
Dosage/Direction for Use
Adult ≥18 yr 250 or 500 mg PO or slow IV infusion every 24 hr or 750 mg slow IV infusion over 90 min every 24 hr. Acute bacterial exacerbation of chronic bronchitis 500 mg every 24 hr for 7 days. Community-acquired pneumonia 500 mg every 24 hr for 7-14 days. Nosocomial pneumonia & complicated SSSI 750 mg every 24 hr for 7-14 days. Acute bacterial sinusitis 500 mg every 24 hr for 10-14 days. Uncomplicated SSSI 500 mg every 24 hr for 7-10 days. Complicated UTI & acute pyelonephritis 250 mg every 24 hr for 10 days. Uncomplicated UTI 250 mg every 24 hr for 3 days. Chronic bacterial prostatitis 500 mg every 24 hr for 28 days. Acute bacterial exacerbation of chronic bronchitis/community-acquired pneumonia/acute bacterial sinusitis/uncomplicated SSSI CrCl 20-49 mL/min Initially 500 mg then 250 mg every 24 hr, CrCl 10-19 mL/min, hemodialysis, CAPD Initially 500 mg then 250 mg every 48 hr. Complicated UTl/acute pyelonephritis CrCl 10-19 mL/min Initially 250 mg then 250 mg every 48 hr.
May be taken with or without food: Administer at least 2 hr before or after antacids containing Mg or Al, as well as sucralfate, Fe & multivit w/ Zn. Ensure adequate fluid intake.
Hypersensitivity to levofloxacin & quinolones.
Special Precautions
Hypersensitivity. Discontinue use if hypoglycemic reaction; phototoxicity; tendon pain, inflammation or rupture occurs. Avoid use in patients w/ history of myasthenia gravis. Known or suspected CNS disorder predisposing to seizures or lowering seizure threshold or in presence of other risk factors; osteochondrosis; convulsions, toxic psychoses; pseudomembranous colitis; overgrowth of clostridia; QT interval prolongation; Torsade de pointes eg, hypokalemia, significant bradycardia, cardiomyopathy. Perform periodic assessment of organ system functions. Monitor blood glucose levels in diabetic patients on oral hypoglycemic agent or insulin. Avoid concurrent use w/ drugs prolonging QT interval eg, class IA & III antiarrhythmics; warfarin. Concomitant use w/ corticosteroids; Mg- or Al-containing antacids, sucralfate, metal cations eg, Fe & multivit prep w/ Zn, or didanosine. Ensure adequate hydration. Avoid excessive sun or UV light exposure. May affect ability to drive or operate machinery. Renal insufficiency. Pregnancy & lactation. Childn & adolescents <18 yr. Elderly. IV: Not to be inj IM, intrathecal, IP or SC. Avoid rapid or bolus inj.
Adverse Reactions
Nausea, headache, diarrhea, insomnia, inj site reaction, constipation. Dizziness, abdominal pain, dyspepsia, vomiting, vaginitis, inj site pain & inflammation, flatulence, pain, pruritus, sinusitis, chest & back pain, fatigue, rash, rhinitis, taste perversion.
Drug Interactions
Prolonged QT interval w/ class IA & III antiarrhythmics, TCAs, macrolides, antipsychotics. Interfered GI absorption w/ Mg- or Al-containing antacids, sucralfate, Fe & multivit prep w/ Zn or didanosine. Prolonged elimination t½, elevated serum theophylline levels & increased risk of theophylline-related AR. Enhanced effects of warfarin. Elevated serum levels of cyclosporine. Increased risk of CNS stimulation & convulsive seizures w/ NSAIDs. Blood glucose disturbances w/ antidiabetics. IV: Not be mixed w/ certain other soln eg, Na hydrogen carbonate or heparin.
MIMS Class
ATC Classification
J01MA12 - levofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Cravit FC tab 250 mg
Cravit IV infusion 500 mg/100 mL
Cravit IV infusion 250 mg/50 mL
Cravit FC tab 500 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in